AMARIN - US Patent's Allowance gives AMR-101 the Lease of Life

March 2012 | 6 pages | ID: A8334DAE7A2EN
MP Advisors

Abstracts

We have maintained a positive view on the approval of AMR-101 (R in US, PDUFA July 26th pharma-grade ethyl icosapentate/omega fatty acid – no DHA) based on its efficacy vs. GSK’s Lovaza (L, omega-3-acid ethyl esters, hypertriglyceridemia), allowance of patent till 2030 (application no. 12/052,598) has now removed the hanging sword. AMRN succeeded in raising funds in January 2012 to challenge Lovaza on its own. More upside is anticipated from… For more details, please read our report released on Mar. 21st, 2011 on AMRN titled “US Patent’s Allowance gives AMR-101 the Lease of Life”.

Contents

COMPANIES MENTIONED

AMARIN